Press Release BioMarin to Participate in Goldman Sachs 12th Annual Healthcare CEOs Unscripted: A View from the Top on January 9, 2020 in New York
Press Release BioMarin to Present at the 22nd Annual Morgan Stanley Global Healthcare Conference on Thursday, September 5 at 7:45 AM PT / 10:45 AM ET in New York, NY
Press Release FDA Grants BioMarin Orphan Drug Designation for NAGLU Fusion Protein, BMN 250, for the Treatment of MPS IIIB (Sanfilippo Syndrome Type B)
Press Release BioMarin Provides 2 Years of Clinical Data in 6e13 vg/kg Dose from Ongoing Phase 1/2 Study in Valoctocogene Roxaparvovec Gene Therapy for Severe Hemophilia A at World Federation of Hemophilia 2018 World Congress
Press Release BioMarin Announces 1 Platform and 3 Poster Presentations at World Federation of Hemophilia 2018 World Congress
Press Release WORLDSymposium Recognizes BioMarin’s Brineura® (cerliponase alfa) with 2018 New Treatment Award
Press Release BioMarin Announces Results for Phase 1 Clinical Study of BMN 195 for Duchenne Muscular Dystrophy
News Post BioMarin Scientist Spotlight: Drs. Sylvia Fong & Soumi Gupta Discuss the Significance of AAV Therapies
